Oncology as On Today Essence of ESMO WCLC 2022 | Welcome & Introduction

IMpower010 : Updated data of phase III Trial of adjuvant Atezolizumab vs BSC in Resected State IB-IIA NSCLC After adjuvant Chemotherapy

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer the INCREASE trial

CANOPU-A Phase III study of canakinumab as adjuvant therapy in patients completely resected non small cell lung cancer

Panel discussion on the abstracts presented at WCLC ESMO

Osimertinib as adjuvant therapy in patients with resected EGFRm Stage IN-IIA NSCLC updated results from ADAURA

Time tp Target Met with VISION in NSCLC

The Growing Evidence of Integrative Oncology for better QoL Improved Treatment Adherence and Survival

Ibrutinib Plus Bendamustine and Rituximab in Previously Untreated Mantle-Cell Lymphoma

Primary Results From the Double-Blind Placebo Controlled Phase III SHINE Study of Ibrutinib

Fixed duration ibrutinib venetoclax for first line treatment

NGS in Hematological malignancies Is it parallel to solid tumors

Benifits of CanAssist Breast in early Breast Cancer patients

Closing Remarks

IMpower010 : Updated data of phase III Trial of adjuvant Atezolizumab vs BSC in Resected State IB-IIA NSCLC After adjuvant Chemotherapy